US Pharma MarketingThe post IceCure enrols initial patients for ProSense cryoablation trial in US appeared first on Medical Device Network.
IceCure enrols initial patients for ProSense cryoablation trial in US
IceCure Medical has enrolled its first two patients across two clinical centres in the US for the ChoICE study assessing its ProSense cryoablation system in low-risk breast cancer treatment. The trial intends to recruit 400 individuals across as many as 30 US trial centres to gather evidence. ProSense holds FDA clearance as the sole medical device indicated for the local treatment of low-risk breast tumours. Credit: Peakstock / Shutterstock.com. IceCure Medical has enrolled its first two patients across two clinical centres in the US for the ChoICE study, assessing its ProSense cryoablation system in low-risk breast cancer treatment. The prospective,…
IceCure Medical has enrolled its first two patients across two clinical centres in the US for the ChoICE study assessing its ProSense cryoablation system in low-risk breast cancer treatment.
Source: Medical Device Network